A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

被引：6
|
作者：
Kwon, Daniel Hyuck-Min [1 ,2 ]
Friedlander, Terence [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
ABIRATERONE; THERAPY;
D O I：
10.21037/atm.2019.09.21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN
    Chi, K. N.
    Thomas, S.
    Agarwal, N.
    Feng, F.
    Attard, G.
    Wyatt, A. W.
    Gormley, M.
    Ricci, D. S.
    Lopez-Gitlitz, A.
    Deprince, K.
    Larsen, J.
    Chen, W.
    Miladinovic, B.
    Naini, V.
    Chowdhury, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Final Analysis Results From TITAN: A Phase III Study of Apalutamide Versus Placebo in Patients With Metastatic Castration-Sensitive Prostate Cancer Receiving Androgen Deprivation Therapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14
  • [43] Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study
    Uemura, Hirotsugu
    Arai, Gaku
    Uemura, Hiroji
    Suzuki, Hiroyoshi
    Iijima, Kazuyoshi
    Nishimura, Kazuo
    Fujii, Koji
    Hatayama, Tomoyoshi
    Aoyama, Junya
    Deprince, Kris
    Lopez-Gitlitz, Angela
    McCarthy, Sharon
    Larsen, Julie S.
    Li, Jinhui
    Chi, Kim N.
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (03) : 280 - 287
  • [44] MEDICAL RESOURCE UTILIZATION (MRU) OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) AND METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): RESULTS FROM SPARTAN AND TITAN
    Agarwal, N.
    Graff, J.
    Dearden, L.
    Heeg, B.
    Wigfield, P.
    VALUE IN HEALTH, 2020, 23 : S52 - S52
  • [45] Original Research Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study
    Merseburger, Axel S.
    Agarwal, Neeraj
    Bhaumik, Amitabha
    Lefresne, Florence
    Karsh, Laurence I.
    Gomes, Andrea J. Pereira de Santana
    Soto, Aalvaro Juarez
    Given, Robert W.
    Brookman-May, Sabine D.
    Mundle, Suneel D.
    Mccarthy, Sharon A.
    Uemura, Hirotsugu
    Chowdhury, Simon
    Chi, Kim N.
    Bjartell, Anders
    EUROPEAN JOURNAL OF CANCER, 2023, 193
  • [46] Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2018, 199 (01): : 26 - 28
  • [47] First-line Therapy for Metastatic Castration-sensitive Prostate Cancer
    Lau, Y. H.
    Wan, L. Y.
    Lam, M. H. C.
    HONG KONG JOURNAL OF RADIOLOGY, 2022, 25 (03): : 244 - 245
  • [48] The cost impact of disease progression to metastatic castration-sensitive prostate cancer
    Quoc-Dien Trinh
    Chaves, Leonardo Passos
    Feng, Qi
    Zhu, Julia
    Sandin, Rickard
    Abbott, Thomas
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (05): : 544 - 554
  • [49] Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer
    Dandapani, Savita V.
    Wong, Jeffrey
    Twardowski, Przemyslaw
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (07) : 490 - 496
  • [50] Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer
    Grisay, Guillaume
    Lavaud, Pernelle
    Fizazi, Karim
    CURRENT ONCOLOGY REPORTS, 2024, 26 (05) : 488 - 495
12345